Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 3410946, 11 pages
Review Article

Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease

1Programa de Pós-Graduação, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2Movement Disorders Department in Neurology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
3Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
4Neurology Program, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

Correspondence should be addressed to Andre C. Felicio; moc.liamg@erdna.fc

Received 19 September 2016; Revised 24 January 2017; Accepted 12 February 2017; Published 5 March 2017

Academic Editor: Antonio Pisani

Copyright © 2017 Tânia M. Bovolenta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil, there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic review critically addresses the various methodologies used in original research around the world in the last decade on the subject, showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information for public health agents is provided.